Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-α, and NF-κB in human endometrial hyperplasia and carcinoma

Cancer

Volumn 95, Issue 7, 2002, Pages 1463-1471

  Vaskivuo, Tommi E ^a   Stenbäck, Frej ^a   Tapanainen, Juha S ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Apoptosis; Bax; Bcl 2; Endometrial carcinoma; Endometrial hyperplasia; NF B; Tumor necrosis factor

Indexed keywords

APOPTOSIS INDUCING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; NEOPLASM STAGING; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036786293     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10876     Document Type: Article

References (54)

1. Bokhman J. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1987;15:7-10.
2. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol. 2000;13:379-388.
3. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
4. Wyllie AH. Apoptosis: cell death in tissue regulation. J Pathol. 1987;153:313-316.
5. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73:2013-2026.
6. Tao XJ, Tilly KI, Maravei DV, et al. Differential expression of members of the bcl-2 gene family in proliferative and secretory human endometrium: glandular epithelial cell apoptosis is associated with increased expression of bax. J Clin Endocrinol Metab. 1997;82:2738-2746.
7. Vaskivuo TE, Stenback F, Karhumaa P, Risteli J, Dunkel L, Tapanainen JS. Apoptosis and apoptosis-related proteins in human endometrium. Mol Cell Endocrinol. 2000;165:75-83.
8. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986;47:19-28.
9. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-1326.
10. Le MG, Mathieu MC, Douc-Rasy S, et al. c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer. 1999;84:562-567.
11. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med. 1997;3:1228-1232.
12. Soda G, Antonaci A, Bosco D, Nardoni S, Melis M. Expression of bcl-2, c-erbB-2, p53, and p21 (wafl-cipl) protein in thyroid carcinomas. J Exp Clin Cancer Res. 1999;18:363-367.
13. Eerola AK, Ruokolainen H, Soini Y, Raunio H, Paakko P. Accelerated apoptosis and low bcl-2 expression associated with neuroendocrine differentiation predict shortened survival in operated large cell carcinoma of the lung. Pathol Oncol Res. 1999;5:179-186.
14. Brady HJ, Gil-Gomez G. The pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol. 1998;30:647-650.
15. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
16. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 1999;399:483-487.
17. Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci. 1995;92:7834-7838.
18. Hanada M, Aime-Sempe C, Sato T, Reed JC. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem. 1995;270:11962-11969.
19. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
20. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-776.
21. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest. 2001;107:241-246.
22. de Martin R, Schmid JA, Hofer-Warbinek R. The NF-kappa-B/Rel family of transcription factors in oncogenic transformation and apoptosis. Mutat Res. 1999;437:231-243.
23. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680-1683.
24. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247-3259.
25. King AE, Critchley HO, Kelly RW. The NF-kappaB pathway in human endometrium and first trimester decidua. Mol Hum Reprod. 2001;7:175-183.
26. Tabibzadeh S, Zupi E, Babaknia A, Liu R, Marconi D, Romanini C. Site and menstrual cycle-dependent expression of proteins of the tumour necrosis factor (TNF) receptor family, and BCL-2 oncoprotein and phase-specific production of TNF alpha in human endometrium. Hum Reprod. 1995; 10:277-286.
27. Saegusa M, Kamata Y, Isono M, Okayasu I. Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. J Pathol. 1996;180:275-282.
28. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol. 1998;29:1150-1159.
29. Henderson GS, Brown KA, Perkins SL, Abbott TM, Clayton F. bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma. Mod Pathol. 1996;9:430-438.
30. Taskin M, Lallas TA, Barber HR, Shevchuk MM. bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol. 1997;10: 728-734.
31. Chan WK, Mole MM, Levison DA, et al. Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J Pathol. 1995;177:241-246.
32. Chieng DC, Ross JS, Ambros RA. bcl-2 expression and the development of endometrial carcinoma. Mod Pathol. 1996;9:402-406.
33. Nakamura T, Nomura S, Sakai T, Nariya S. Expression of bcl-2 oncoprotein in gastrointestinal and uterine carcinomas and their premalignant lesions. Hum Pathol. 1997;28:309-315.
34. Niemann TH, Trgovac TL, McGaughy VR, Vaccarello L. bcl-2 expression in endometrial hyperplasia and carcinoma. Gynecol Oncol. 1996;63:318-322.
35. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. Gynecol Oncol. 1998;71:305-307.
36. Athanassiadou P, Petrakakou E, Liossi A, et al. Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium. Acta Cytol. 1999;43:1039-1044.
37. Peiro G, Diebold J, Baretton GB, Kimmig R, Lohrs U. Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with Bcl-2, Bax, and caspase-3 expression and outcome. Int J Gynecol Pathol. 2001;20:359-367.
38. Lyons SK, Clarke AR. Apoptosis and carcinogenesis. Br Med Bull. 1997;52:554-569.
39. Gerschenson LE, Fennell RH. A developmental view of endometrial hyperplasia and carcinoma based on experimental research. Path Res Pract. 1982;174:285-296.
40. Wyllie AH. Apoptosis and carcinogenesis. Eur J Cell Biol. 1997;73:189-197.
41. Törmanen U, Eerola AK, Rainio P, et al. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res. 1995;55:5595-5602.
42. Aihara M, Scardino PT, Truong LD, et al. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer. 1995;75:522-529.
43. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the bcl2 family and cell death. Blood. 1996;88:386-401.
44. Marone M, Ferrandina G, Macchia G, et al. Bcl-2, Bax, Bcl-x(L) and Bcl-x(S) expression in neoplastic and normal endometrium. Oncology. 2000;58:161-168.
45. Ouyang H, Furukawa T, Abe T, Kato Y, Horii A. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res. 1998;4:1071-1074.
46. Tabibzadeh S, Satyaswaroop PG, von Wolff M, Strowitzki T. Regulation of TNF-alpha mRNA expression in endometrial cells by TNF-alpha and by oestrogen withdrawal. Mol Hum Reprod. 1999;5:1141-1149.
47. Zupi E, Sbracia M, Marconi D, et al. TNFalpha expression in hyperplastic endometrium. Am J Reprod Immunol. 2000;44:153-159.
48. Garcia FU, Chen HL, Yang Y, Pace JL, Hu XL, Hunt JS. Tumor necrosis factor-alpha mRNA and protein in endometrial tumors: analysis by in situ hybridization and immunocytochemistry. Hum Pathol. 1994;25:1324-1331.
49. Chopra V, Dinh TV, Hannigan EV. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol. 1997;123:167-172.
50. Wang CY, Mayo MW, Baldwin AS. TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996;274:787.
51. McDade TP, Perugini RA, Vittimberga FJ, Carrigan RC, Callery MP. Salicylates inhibit NF-κB activation and enchance TNF-α-induced apoptosis in human pancreatic cancer cells. J Surg Res. 1999;83:56-61.
52. Kalkhoven E, Wissink S, van der Saag PT, van der BB. Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor. J Biol Chem. 1996;271:6217-6224.
53. Higgins KA, Perez JR, Coleman TA, et al. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci. 1993;90:9901-9905.
54. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 2001;20:4188-4197.